Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2014; 6(5): 315-325
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315
Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation
Chrysoula Pipili, Evangelos Cholongitas
Chrysoula Pipili, Department of Nephrology, Laiki Merimna, 17343 Athens, Greece
Evangelos Cholongitas, 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece
Author contributions: Pipili C and Cholongitas E both contributed to this paper.
Correspondence to: Evangelos Cholongitas, Assistant Professor, 4th Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki, 49, Konstantinopoleos Street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Telephone: +30-23-10892110 Fax: +30-23-10992940
Received: December 3, 2013
Revised: March 10, 2014
Accepted: April 16, 2014
Published online: May 27, 2014
Core Tip

Core tip: While nucleos(t)ide analogs (NAs) offer a benign course in patients with hepatitis B virus before and after liver and renal transplantation, there is still scope for improvement. The administration of high genetic barrier NAs such as entecavir or tenofovir pre-transplant and the careful patient selection for hepatitis virus immunoglobulin-free regimens post-transplant contribute to improved medical care and facilitate its provision from a practical standpoint. Concordantly, attention has turned to new treatment strategies regarding hepatitis C virus recurrence after liver and renal transplantation. The addition of oral direct acting antivirals to the existing treatment marks a promising strategy for prognosis amelioration of these patients.